Drugs / BO-112
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04777708 | Oct 2021 → Mar 2023 | hepatocellular carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02828098 | Jun 2016 → Jul 2020 | cancer | Highlight Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05265650 | Jun 2022 → Mar 2024 | non-small cell lung carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT06422936 | May 2024 → Dec 2026 expected | basal cell carcinoma | Highlight Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04570332 | Dec 2020 → Oct 2023 | melanoma | Highlight Therapeutics | Completed | Met primary |
| Phase 2 | NCT04508140 | Jun 2020 → Dec 2022 | colorectal cancer, esophageal cancer, gastric cancer | Highlight Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Highlight Therapeutics | Results BO-112 shows promising results in patients with immunotherapy-resistant melanoma highlighttherapeutics.com ↗
The data, presented at the 2022 Annual Meeting of the American Association for Cancer Research (AACR), confirm the potential of BO-112 as a new second-line therapy with high efficacy for these patients. |
| 2021-12-02 | Highlight Therapeutics | Results A new combination that expands the potential of immunotherapy highlighttherapeutics.com ↗
On this occasion, together with the team at the Cima Universidad de Navarra, we have published positive results from a preclinical study in the journal Journal for ImmunoTherapy of Cancer (JITC) demonstrating the efficacy of combining BO-112 with a STING agonist. |
| 2021-11-12 | Highlight Therapeutics | Results BO-112 shows positive preliminary results in advanced melanoma resistant to immunotherapy highlighttherapeutics.com ↗
On this occasion, we are sharing the positive preliminary results from the phase IIb clinical study of BO-112, presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held in Washington, D.C. |
| 2019-12-12 | Highlight Therapeutics | Results BO-112 debuts at ESMO IO 2019: first clinical data from a Spanish immuno-oncology program highlighttherapeutics.com ↗
The findings point in a promising direction: the combination proved to be safe, well tolerated, and showed early signals of clinical activity in tumors that had developed resistance. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Highlight Therapeutics | BO-112 shows promising results in patients with immunotherapy-resistant melanoma highlighttherapeutics.com ↗ |
| 2021-12-02 | Highlight Therapeutics | A new combination that expands the potential of immunotherapy highlighttherapeutics.com ↗ |
| 2021-11-12 | Highlight Therapeutics | BO-112 shows positive preliminary results in advanced melanoma resistant to immunotherapy highlighttherapeutics.com ↗ |
| 2021-03-02 | Highlight Therapeutics | Highlight Therapeutics and Pivotal launch a new clinical trial with BO-112 in advanced melanoma highlighttherapeutics.com ↗ |
| 2020-06-26 | Highlight Therapeutics | BO-112 continues to advance: launch of a study in liver metastases highlighttherapeutics.com ↗ |
| 2019-12-12 | Highlight Therapeutics | BO-112 debuts at ESMO IO 2019: first clinical data from a Spanish immuno-oncology program highlighttherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BO-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05265650 ↗ |
| Modality | Oligonucleotide (other) | “synthetic, double-stranded RNA” PMID 40577656 ↗ Jun 2025 |
| Route | Other | “intratumorally delivered BO-112” PMID 31046839 ↗ May 2019 |